Apple Pharmaceuticals

Abiramale 500 - Abiraterone Acetate 500mg Tablets

Description:
Abiramale 500 contains Abiraterone acetate 500mg is an orally administered prodrug of abiraterone, a selective inhibitor of the enzyme CYP17A1, which is involved in androgen biosynthesis. It is primarily used in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Uses:
Abiramale 500 - Abiraterone acetate 500mg tablet is indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. It is also sometimes used in metastatic high-risk castration-sensitive prostate cancer.

Metabolism:
After oral administration, abiraterone acetate is rapidly converted in vivo to abiraterone, its active form. Abiraterone is metabolized mainly in the liver via the CYP3A4 pathway and, to a lesser extent, by SULT2A1.

Adverse Effects:
Common adverse effects include hypertension, hypokalemia, fluid retention, liver function abnormalities, joint swelling or discomfort, and hot flushes. Rare but serious effects include hepatotoxicity and cardiac disorders.

Distribution:
Abiraterone is highly protein-bound (>99%) in plasma. It is widely distributed in the body, but does not significantly cross the blood-brain barrier.

Excretion:
Abiraterone and its metabolites are primarily excreted via the feces (about 88%), with a minor proportion excreted in urine (about 5%).

Dosage:
The recommended dose is 1000 mg (two 500mg tablets) taken once daily on an empty stomach, in combination with prednisone 5 mg administered orally twice daily. Dosage adjustments may be required in cases of hepatic impairment.